UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K
                    ----------------------------------------

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                    -----------------------------------------

Date of Report (Date of earliest event reported) May 8, 2006
                                                ------------
                           VION PHARMACEUTICALS, INC.
                           --------------------------
             (Exact Name of Registrant as Specified in its Charter)

       Delaware                         000-26534               13-3671221
------------------------------       -----------------      --------------------
(State or Other Jurisdiction           (Commission             (IRS Employer
     of Incorporation)                 File Number)          Identification No.)

     4 Science Park, New Haven, CT                                    06511
----------------------------------------                            ---------
(Address of Principal Executive Offices)                            (Zip Code)

Registrant's telephone number, including area code: (203) 498-4210
                                                   ----------------

                                 Not Applicable
 -------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[  ] Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17 CFR 240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))





SECTION 2 - FINANCIAL INFORMATION.

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

     On May 8, 2006, the Registrant issued a press release reporting its
financial results for the quarter ended March 31, 2006. A copy of that press
release is being furnished to the Securities and Exchange Commission pursuant to
this Item 2.02 of Form 8-K and is attached hereto as Exhibit 99.1.

SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS.

ITEM 9.01(D)  EXHIBITS.

Exhibit 99.1  Press release dated May 8, 2006.


                                        2



                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                           VION PHARMACEUTICALS, INC.



Date: May 9, 2006          By: /s/ Howard B. Johnson
                              ----------------------------------------
                               Name: Howard B. Johnson
                               Title:   President and Chief Financial Officer


                                        3





                                  EXHIBIT INDEX
                                  -------------

99.1  Press release dated May 8, 2006.